1801923864
The BioHub: The Top Voices in Biotech

Advertise on podcast: The BioHub: The Top Voices in Biotech

Rating
★★★★★
5
from
1 reviews
This podcast has
285 episodes
Language
English
Date created
2025/03/13
Latest episode
2026/11/11
Average duration
29 min.
Release period
3 days

Description

Welcome to The BioHub, where the doors to the world of biotechnology swing wide open. Join your host, Max Brennan, a seasoned biotech recruiter, as he engages in thought-provoking conversations with the brightest minds in biotech. This podcast is your backstage pass to the insights, strategies, and stories that fuel success in the dynamic and ever-evolving biotech landscape. Subscribe now and be part of the conversation that's shaping the future of biotechnology. Get ready for an immersive experience into the world of biotech with The BioHub.

Unlock The BioHub: The Top Voices in Biotech podcast Email contact info,
Listeners & Audience details

Email contact information

Direct podcast contact details

Listeners

Audience numbers & engagement insights

Audience details

Podcast Insights

Podcast episodes

Check latest episodes from The BioHub: The Top Voices in Biotech podcast


Episode 259 - Hannah Shen Founder & CEO - Kekulai
2026/11/11
In this episode of the BioHub podcast, Amber Hayes is joined by Hannah Shen, Founder and CEO of Kekulai, an end-to-end agentic drug discovery company focused on developing first-in-class medicines. Drawing on her experience at Benchling and BridgeBio, Hannah shares her journey into biotech and the vision behind Kekulai's agentic discovery platform, Alchemy. Together, they explore the challenges of building reliable AI agents for high-stakes scientific decisions, balancing human expertise with autonomous workflows, and why more data doesn't always mean better drug discovery. Hannah also discusses how Kekulai is running three drug A fascinating conversation about the future of agentic AI, scientific reasoning and what it takes to turn emerging technology into real medicines.
Episode 258 - Susan Hill CEO & Board Member at Mestag Therapeutics
2026/11/10
We were delighted to be joined by Susan Hill, CEO and founder of Mestag Therapeutics, a biotechnology company pioneering new approaches to treating cancer and inflammatory diseases through the emerging field of fibroblast immunology. Susan brings more than 25 years of experience across the biotechnology, pharmaceutical and investment industries. She has held senior leadership positions at Merck KGaA, Alexion, Freeline Therapeutics and Gyroscope Therapeutics, where she served as Chief Business Officer before its acquisition by Novartis. She founded Mestag Therapeutics in 2020, building the company around some fascinating science and leading it through significant financing, strategic pharmaceutical partnerships and its evolution into a clinical-stage biotech. Mestag is tackling an area of biology that has historically been overlooked, exploring how fibroblasts interact with the immune system and how those interactions could unlock entirely new therapeutic approaches for patients. Today, we'll be discussing Susan's journey through the field, the experience of building and scaling biotech companies, the science behind Mestag, and what it takes to translate emerging biology into impactful medicines.
Episode 257 - Aarash Bordbar, CEO & Co-Founder at Sinopia Biosciences
2026/11/05
Today on The BioHub, I'm delighted to be joined by Dr. Aarash Bordbar, Co-Founder and Chief Executive Officer of Sinopia Biosciences. Aarash has built his career at the intersection of computational biology, systems biology and drug discovery, with a particular focus on understanding complex biological systems and translating that knowledge into new therapeutic approaches. He co-founded Sinopia Biosciences with a vision of harnessing computational modelling and data-driven approaches to transform drug discovery, bringing together biology, mathematics and technology to tackle some of the most challenging questions in medicine. Today, we're going to explore Aarash's journey through the field, the founding and evolution of Sinopia, how computational biology is changing the drug discovery landscape, and what the future might look like as AI and advanced modelling become increasingly integrated into biotechnology.
Episode 256 - Sean Ekins - Collaborations Pharmaceuticals
2026/11/04
In this episode of The BioHub, Amber is joined by Dr. Sean Ekins, Founder and CEO of Collaborations Pharmaceuticals. Sean shares his perspective on the evolving role of machine learning in drug discovery, how computational approaches can support rare and neglected disease research, and what it really takes to move from prediction to meaningful therapeutic development. They also discuss the opportunities and limitations of AI in chemistry, the importance of scientific collaboration, and some of the wider questions around responsible innovation and dual-use risk as generative drug discovery continues to develop.
Episode 255 - Jason Goodson - COO at PleoPharma
2026/11/02
n this episode of The BioHub, we welcome Jason Goodson, Chief Operating Officer at PleoPharma, a clinical-stage biotechnology company developing innovative treatments for cannabis use disorder and cannabis withdrawal syndrome. With millions of Americans affected by cannabis use disorder and no FDA-approved medications specifically targeting cannabis withdrawal, PleoPharma is working to address a significant unmet need through its lead candidate, PP-01, now in pivotal Phase 3 development. Jason shares insights into the growing market for addiction therapeutics, the clinical and commercial potential of PP-01, and the challenges of bringing a first-in-class treatment to market. We also explore the strategic decisions behind scaling a clinical-stage biotech, from financing and partnerships to commercial readiness, leadership, and building the right team for future growth.
Episode 254 - Erick Lucera (CFO) & Vikram Ranade (CBO) at Dyne Therapeutics
2026/10/29
Today, we’re joined by Erick Lucera, Chief Financial Officer, and Vikram Ranade, Chief Business Officer at Dyne Therapeutics. We’ll be discussing their individual journeys through biotech, what attracted them to Dyne, and the company’s mission to develop transformative treatments for people living with genetically driven neuromuscular diseases. We’ll also explore the strategy behind building a biotech towards commercialisation, the financial and business development challenges involved, and their perspectives on the wider biotech landscape.
Episode 253 - John Yu CEO at Kairos Pharma
2026/10/26
In this episode of The BioHub Podcast, Ben is joined by Dr. John Yu, CEO and Chairman of Kairos Pharma, a clinical-stage biotechnology company developing innovative therapies to overcome drug resistance and immune suppression in cancer. Dr. Yu brings a unique perspective from his extensive career in neurosurgery, oncology, immunology, and biotechnology entrepreneurship. Together, they explore his journey from academic medicine into biotech leadership, the science behind Kairos Pharma's approach to tackling cancer drug resistance, and the development of its lead candidate, ENV105, which targets CD105 to potentially restore sensitivity to existing cancer treatments. The conversation also examines the challenges of translating academic discoveries into clinical therapies, building and financing an emerging biotechnology company, and the opportunities ahead for improving cancer treatment outcomes. An insightful discussion on scientific innovation, entrepreneurship, and the journey from breakthrough research to meaningful patient impact.
Episode 252 - Sam Reich - CEO at SAB Bio
2026/10/26
In this episode of The BioHub by Avetix, I’m joined by Sam Reich, CEO of SAB BIO. Sam shares his unconventional journey from leaving his PhD to build his first biotech, through founding and selling companies, working with influential industry figures like Phil Frost, and eventually leading Big Cypress Acquisition Corp. We discuss how that journey brought him to SAB BIO, why the company became the right opportunity, the challenges behind its strategic pivot towards type 1 diabetes, and what it takes to keep adapting when the path of a biotech changes. We also explore the lessons Sam has learned from building, financing and leading companies across multiple stages, and what comes next for SAB as it works to develop a disease-modifying treatment for type 1 diabetes.
Episode 250 - Dr. Garry Pairaudeau, Co-Founder CEO & Dr. Anthony Bradley, Co-Founder CSO of Dalton Tx
2026/10/22
In this episode of The BioHub, Amber is joined by Dr. Garry Pairaudeau, Co-Founder and CEO, and Dr. Anthony Bradley, Co-Founder and CSO of Dalton Tx. Having previously worked together at Exscientia, Garry and Anthony went on to co-found Dalton Tx. bringing together AI, scientific expertise and software engineering to help accelerate drug discovery. We explore their journey the challenges of translating advances in AI into meaningful scientific impact, and the importance of separating genuine innovation from industry hype. We also discuss the evolving role of AI in drug discovery, building a science-driven company, and what the future could hold for AI-enabled therapeutics.
Why Biotech Keeps Reinventing the Wheel | Greg Crescenzi, Addgene
2026/10/21
Why spend months recreating research tools that another lab has already built? In this episode of The BioHub, we’re joined by Greg Crescenzi from Addgene to discuss how sharing scientific materials can reduce duplicated work, save researchers time and help biotech discoveries move faster. From plasmids and CRISPR tools to viral vectors and antibodies, Greg explains how Addgene helps scientists build on existing research—and why improving access between academia and industry is the next challenge. We cover: • The frustration that sparked Addgene’s founding• How sharing research tools helped CRISPR reach thousands of organisations• The barriers between academic research and commercial biotech• Partnerships supporting better sequencing and new research tools• Why unsuccessful experiments contain information worth sharing• Where AI and Addgene’s research data could create new opportunities Subscribe to The BioHub for more conversations with the people advancing biotech. #Biotech #Addgene #CRISPR #BioHub
Episode 248- Marshall Fordyce - Founder & CEO of Vera Therapeutics
2026/10/20
In this episode of The BioHub by Avetix, I’m joined by Marshall Fordyce, Founder and CEO of Vera Therapeutics. Marshall shares his journey from medicine and HIV drug development at Gilead to founding Vera, and how that experience shaped his belief in the power of building medicines that can genuinely change the course of disease. We discuss what patient-centricity looks like in practice, the thinking behind Vera’s Phase III strategy, and the company’s transition from development-stage biotech into commercial launch. Marshall also shares his framework for building biotech companies, why people and capital discipline matter just as much as the science, and what comes next for Vera as it continues the US launch of Trutacna.
Episode 247 - Chris Moxham Founder & CEO and Clayton Mellina CTO of Transcripta Bio
2026/10/19
In this episode of The BioHub, Amber is joined by Dr. Chris Moxham, Co-founder and CEO of Transcripta Bio, and Clayton Mellina, CTO, to explore how transcriptomics and AI are opening up new possibilities in drug discovery. Chris and Clayton explain how Transcripta connects the changes disease causes in cells with the effects of potential treatments. They discuss combining phenotypic screening with target-based discovery, finding new uses for existing medicines, and reducing risk earlier in development. The conversation covers their work in genetically defined autism spectrum disorders and Huntington’s disease, their collaboration with Mayo Clinic, and how AI agents could help small scientific teams explore thousands of hypotheses.
Episode 246 - Neil Warma - CEO, ProMIS Neurosciences
2026/10/19
In this episode of The BioHub Podcast by Avetix, we welcome Neil Warma, President and CEO of ProMIS Neurosciences, a clinical-stage biotechnology company developing next-generation therapies targeting toxic, misfolded proteins associated with neurodegenerative diseases. Neil shares insights from his extensive career building and leading biotechnology companies, before exploring ProMIS' differentiated approach to treating Alzheimer's disease. We discuss PMN310, an antibody designed to selectively target toxic amyloid-beta oligomers while avoiding plaque, its ongoing Phase 1b PRECISE-AD clinical trial, and the potential to improve both efficacy and safety in Alzheimer's treatment. The conversation also explores ProMIS' broader ambitions across ALS and Parkinson's disease, upcoming clinical milestones, and Neil's perspective on leadership, financing, and building successful biotechnology companies.
Episode 245 - Michael Fenn CBO Bexorg
2026/10/14
On this episode of The BioHub, Amber Hayes is joined by Michael Fenn, Chief Business Officer at Bexorg, a precision neurology company combining AI with a pioneering whole-human brain platform to transform CNS drug discovery. Michael brings experience spanning biotech investing, business development and company building, including previous roles at Dewpoint Therapeutics and Iaso Ventures. He shares his journey across the industry, what attracted him to Bexorg, and why he believes the company’s approach could fundamentally change how neurological therapies are discovered and developed. We discuss the challenges of translating neuroscience research into effective treatments, how Bexorg is combining human brain pharmacology with AI to bridge the gap between preclinical research and clinical success, and the opportunities and challenges of building a platform-driven biotech.
Episode 244 - Erik Wiklund & Thomas Hansen - CEO & CTO of Circio
2026/10/12
On this episode, we sit down with the CEO & CTO of Circio to get into the world of circular RNA. Erik, Thomas and the team are developing circVec, a circular RNA expression platform designed to make C&G therapies more powerful and durable. The guys dig into the science & history behind circular RNA before discussing some initial data they have in heart, brain and other tissues, whilst explaining why this matters. We also touch on the platform vs internal pipeline debate, their recent fundraising, partnering discussions and what to expect from Circio in the next 18 months.

Podcast reviews

Read The BioHub: The Top Voices in Biotech podcast reviews


5 out of 5
1 reviews

Podcast sponsorship advertising

Start advertising on The BioHub: The Top Voices in Biotech relevant audience podcasts


What do you want to promote?